Home » Health and medicine » Diagnostics » News Digest #216 – Synthorx raises $63M, new startup Mammoth uses CRISPR to tackle diagnostics

News Digest #216 – Synthorx raises $63M, new startup Mammoth uses CRISPR to tackle diagnostics


Hi all,

This week, Mammoth Biosciences, co-founded by Jennifer Doudna, launched the world’s first and only CRISPR-enabled platform capable of detecting any biomarker or disease containing DNA or RNA. The technology could replace the need for dedicated testing devices, while also increasing accessibility and ease-of-use.

“With use cases ranging from individuals to larger healthcare systems, agriculture, mining, and beyond, Mammoth is taking CRISPR out of the lab to create something that is transformative for the general public”, said co-founder Jennifer Doudna.

Synthorx raised $63 million in Series C financing to advance the development of Synthorin cytokines, which use the company’s expanded genetic alphabet technology. Cytokines enhance the antitumor activity of checkpoint inhibitors, cancer vaccines, CAR-T therapies, and oncolytic viruses.

Laura Shawver, president, CEO, and director of Synthorx.

Feng Zhang of the Broad Institute has co-founded another CRISPR startup, Beam Therapeutics, which has raised the first $13 million of a Series A financing round.

The Center for Excellence in Engineering Biology and the leadership of Genome Project-write (GP-write) announced its first grand-scale community-wide project: to develop “ultra-safe cells” that resist natural viruses, plus partial resistance to aging, cancer, and other harms.

Finally, Ryan Bethencourt, CEO of Wild Earth, is leading the charge towards a different kind of pet food. With the first fungi-based plant food launching late 2018, they are at the forefront of a new approach to feeding animals. The company kicked off with $4 million and their plan is to go after the entire pet food market.

Have a great rest of the week.

Singapore bets big on synthetic biology
FDA approves first genetically engineered salmon farm in US
Can ExxonMobil use synthetic biology to commercialize algae fuels?
Harvard’s Wyss Institute partners with Cellectis to recode the human genome
Five amazing ways redesigning biological cells could help us fight cancer
Yield10 discusses application of metabolic engineering to increase crop yield

All the News

Researchers build DNA replication in a model synthetic cell (TU Delft)

Genome writing project aims to rally scientists around virus-proofing cells (Science News)

DARPA enlists insects in R&D effort to protect the food supply (Xconomy)

A biodesigned world: what are we waiting for? (Cambridge Consultants)

Synthace appoints Bob Wiederhold as Chairman of its board of directors (Press release)

Renaissance BioScience partners with Mitacs for $1.44-million project to advance its next-generation yeast development platform (Press release)

Bristol researchers use gene editing to improve red blood cell transfusion compatibility

The present and future state of synthetic biology in Canada

BIO announces Gene Editing and Synthetic Biology programming for 2018 World Congress

Molecular Devices and ForteBio to drive integrated workflow for drug discovery (Press release)

Bio-Botanica partners with Genomatica to create botanical extract line for personal care (Press release)

Who’s Hiring?

DNA Synthesis Lead: Joint Genome Institute, California, United States

Synthetic Biologist / Geneticist: Eligo Bioscience, Paris, France

Synthetic biologist/Protein engineer: XENO Cell Innovations, Pilsen, Czech Republic

Director of Science Education: Genspace, Brooklyn, NY

Community Lab Biosafety Officer Fellowship: Genspace, BUGSS and Biocurious

To feature your job here, please get in touch

Copyright © %%current_year_YYYY%%, All rights reserved.

1547 Palos Verdes Mall, #411
Walnut Creek, CA 94597

About Us | Update Preferences | Unsubscribe | View email in your browser

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Editor’s picks